Politicians with a vested interest in their campaigns and the way public policy has been shaped and produced to this day. In addition to money spent on lobbyists and politicians, these institutions play a major role in ensuring they produce the right message and bring together members who could turn a blind eye to abuses and discrimination.

As such, the main beneficiaries of this largesse come from various other sectors besides the corporate, government (corporations and big money), the general public and the public-private partnerships.

Over the years, there has been a remarkable increase in this sector. Within industry, the corporate-government/corporting power has grown substantially. And as public infrastructure and public services become more integrated via public procurement initiatives and corporate involvement, the public and private sectors also have seen their influence decrease dramatically.

Analyses of the recent financial crisis have suggested that many of the sector's biggest clients are often directly benefitting these donors.

It is hard for me to see in a few years here a scenario where a major new industry with major investments in infrastructure and public services as a primary target for its donors, such as the US pharmaceutical companies, should become more involved in the public policy process. I suggest that this is precisely where the public service sector really needs to be focused.

While the US pharmaceutical industry is a large and profitable player in many ways, it faces significant challenges with respect to regulatory compliance.